Delcath Systems
DCTH
14.67
-0.71
-4.62%
Delcath Systems
US · DCTH
#3706 by market cap
14.67
-0.71
-4.62%
Live - 5344 symbols - heartbeat 21s ago
· 2026-10-08 10:11
After-hours
15.38
0.00%
- Market cap
- 509.03M
- P/E (TTM)i
- 1,467.00
- P/Bi
- 4.20
- EPSi
- 0.07
- Div yieldi
- 0.00%
- 52W posi
- 70%
Reader sentiment
Are you bullish or bearish on DCTH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 20.38, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +129.08% YoY
Margins
- Gross margin
- 86.16%
- Operating margin
- 0.77%
- Net margin
- 3.17%
Key ratios & quality
- Altman Z-Scorei
- 20.38
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 3.56M | 2.72M | 2.07M | 37.21M | 85.23M |
| Gross profit | 2.40M | 861.00K | 1.01M | 2.88M | 2.03M | 1.43M | 31.02M | 73.43M |
| Selling & admin expenses | 9.82M | 11.28M | 11.11M | 13.64M | 17.30M | 22.11M | 29.55M | 43.53M |
| Research & development | 19.65M | 9.49M | 11.20M | 13.78M | 18.58M | 17.50M | 13.87M | 29.25M |
| Operating profit | -27.07M | -19.91M | -21.30M | -24.53M | -33.85M | -38.18M | -12.41M | 660.00K |
| Pretax profit | -19.22M | -8.88M | -24.16M | -25.65M | -36.51M | -47.68M | -26.39M | 3.51M |
| Tax | -- | -- | -- | -- | -- | -- | 0 | 810.00K |
| Net profit | -19.22M | -8.88M | -24.16M | -25.65M | -36.51M | -47.68M | -26.39M | 2.70M |
| Basic EPS | -504 | -343 | -8 | -4 | -4 | -3 | -1 | 0 |
| Diluted EPS | -504.00 | -342.83 | -8.35 | -3.59 | -4.12 | -2.94 | -0.93 | 0.07 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 19.78M | 24.16M | 20.56M | 20.73M | 24.99M | 29.13M |
| Gross profit | 16.94M | 20.84M | 17.94M | 17.72M | 21.26M | 26.15M |
| Selling & admin expenses | 11.29M | 11.37M | 10.34M | 10.53M | 13.07M | 13.37M |
| Research & development | 5.01M | 6.88M | 7.99M | 9.37M | 9.82M | 10.38M |
| Operating profit | 642.00K | 2.59M | -388.00K | -2.18M | -1.64M | 2.40M |
| Pretax profit | 1.26M | 3.21M | 375.00K | -1.33M | -908.00K | 3.16M |
| Tax | 195.00K | 508.00K | -455.00K | 562.00K | 162.00K | 491.00K |
| Net profit | 1.07M | 2.70M | 830.00K | -1.90M | -1.07M | 2.67M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.03 | 0.07 | 0.02 | -0.05 | -0.03 | 0.07 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 5.92M | 12.62M | 32.34M | 31.15M | 16.16M | 37.16M | 73.76M | 119.53M |
| Cash & ST investments | 2.52M | 10.00M | 28.58M | 22.80M | 7.67M | 32.45M | 53.23M | 91.04M |
| Inventory | 858.00K | 654.00K | 855.00K | 1.41M | 2.00M | 3.32M | 6.93M | 10.25M |
| Total assets | 6.84M | 14.21M | 34.64M | 33.12M | 17.86M | 38.61M | 76.59M | 123.63M |
| Total current liabilities | 17.75M | 15.99M | 10.04M | 5.95M | 14.74M | 16.45M | 6.14M | 10.95M |
| Short-term debt | 2.04M | 664.00K | 2.50M | 1.04M | 8.03M | 10.19M | 105.00K | 101.00K |
| Long-term debt | -- | 2.00M | -- | 15.01M | 7.84M | -- | -- | -- |
| Total liabilities | 21,783,000.00 | 20,569,000.00 | 12,557,000.00 | 21,172,000.00 | 23,721,000.00 | 22,836,000.00 | 7,843,000.00 | 12,413,000.00 |
| Total equity | -14.94M | -6.36M | 22.08M | 11.95M | -5.86M | 15.78M | 68.75M | 111.22M |
| Retained earnings | -344.05M | -371.17M | -395.33M | -420.98M | -457.48M | -505.16M | -531.55M | -528.85M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 84.35M | 113.48M | 120.62M | 119.53M | 120.27M | 130.54M |
| Cash & ST investments | 58.90M | 81.01M | 88.91M | 91.04M | 89.30M | 95.90M |
| Inventory | 7.13M | 10.52M | 10.75M | 10.25M | 9.81M | 11.71M |
| Total assets | 87.32M | 116.88M | 124.30M | 123.63M | 124.84M | 137.02M |
| Total current liabilities | 5.29M | 10.44M | 8.01M | 10.95M | 10.70M | 13.28M |
| Short-term debt | 110.00K | 116.00K | 110.00K | 101.00K | 92.00K | 196.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 7,089,000.00 | 11,890,000.00 | 9,448,000.00 | 12,413,000.00 | 12,128,000.00 | 15,873,000.00 |
| Total equity | 80.23M | 104.99M | 114.85M | 111.22M | 112.71M | 121.15M |
| Retained earnings | -530.48M | -527.78M | -526.95M | -528.85M | -529.92M | -527.25M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -14.73M | -23.69M | -22.87M | -22.60M | -24.95M | -31.25M | -18.68M | 22.52M |
| Depreciation & amortization | 444.00K | 249.00K | 167.00K | 146.00K | 132.00K | 399.00K | 229.00K | 349.00K |
| Free cash flow | -14.81M | -23.71M | -23.65M | -22.75M | -25.16M | -31.31M | -19.24M | 20.97M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 10.92M | 0 | 39.76M | 3.92M | 10.86M | 23.08M | 7.02M | -5.52M |
| Ending cash balance | 3.58M | 10.18M | 28.76M | 26.95M | 11.82M | 12.70M | 32.41M | 43.45M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 2.20M | 7.29M | 4.77M | 8.25M | 857.00K | 5.71M |
| Depreciation & amortization | 67.00K | 27.00K | 146.00K | 109.00K | 131.00K | 84.00K |
| Free cash flow | 2.06M | 6.90M | 4.31M | 7.70M | 287.00K | 5.21M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 238.00K | -238.00K | -5.52M | -3.00M | 378.00K |
| Ending cash balance | 12.78M | 34.42M | 41.81M | 43.45M | 41.31M | 47.52M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -308.01 | -150.74 | -1,198.36 | -961.44 | -62.44 | 3.00 |
| ROA %i | -244.38 | -84.34 | -99.13 | -75.71 | -143.21 | -168.85 | -45.81 | 2.70 |
| ROIC %i | -- | -- | -223.31 | -91.91 | -176.98 | -328.67 | -54.58 | 2.97 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -536.20 | -474.00 |
| EBIT margin %i | -330.58 | -261.58 | -1,456.93 | -688.13 | -1,243.95 | -2,239.18 | -33.36 | 0.77 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 24.60 |
| Current ratioi | 0.33 | 0.79 | 3.22 | 5.23 | 1.10 | 2.26 | 12.01 | 10.92 |
| Quick ratioi | 0.21 | 0.63 | 2.85 | 3.84 | 0.55 | 2.00 | 10.46 | 9.50 |
| Debt / assetsi | 29.78 | 20.13 | 8.50 | 48.45 | 88.87 | 26.38 | 1.36 | 0.76 |
| LT debt / equityi | -- | -- | 2.04 | 125.59 | -- | -- | 1.36 | 0.75 |
| Interest coveragei | -1.42 | -0.87 | -137.03 | -20.63 | -12.60 | -32.13 | -- | -- |
| Revenue CAGR (3Y) %i | 24.94 | -7.43 | -15.36 | 1.43 | 19.84 | 7.85 | 118.74 | 215.30 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -29.95 | 4.09 | 1.94 | 3.00 | 0.58 | 0.47 |
| ROA %i | -23.02 | 2.96 | 1.54 | 2.70 | 0.53 | 0.42 |
| ROIC %i | -27.23 | 3.86 | 1.88 | 2.97 | 0.58 | 0.46 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -2.77 | 7.14 | 7.39 | 0.77 | -1.79 | -1.90 |
| FCF / sales %i | -- | 5.51 | 15.12 | 24.60 | 21.22 | 18.35 |
| Current ratioi | 15.95 | 10.88 | 15.06 | 10.92 | 11.24 | 9.83 |
| Quick ratioi | 13.86 | 9.37 | 13.04 | 9.50 | 9.77 | 8.50 |
| Debt / assetsi | 1.16 | 0.85 | 0.78 | 0.76 | 0.73 | 1.80 |
| LT debt / equityi | 1.13 | 0.84 | 0.74 | 0.75 | 0.72 | 1.87 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Hepzato Kit is the largest reported line at 93.23% of revenue, across 2 reported segments.
- The next-largest line, Chemosat, is a distant second at 6.77% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Hepzato Kit93.23%
Chemosat6.77%
Quote time 2026-10-08 10:11:35 · For reference only, not investment advice and not tailored to your situation.